Relyea Zuckerberg Hanson LLC lifted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 39.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,448 shares of the biopharmaceutical company’s stock after purchasing an additional 4,680 shares during the quarter. Relyea Zuckerberg Hanson LLC’s holdings in Pfizer were worth $603,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. 25 LLC acquired a new stake in Pfizer during the 1st quarter worth about $25,000. Worth Asset Management LLC purchased a new position in Pfizer during the 1st quarter valued at about $29,000. Freedom Wealth Alliance LLC purchased a new position in Pfizer during the 4th quarter valued at about $35,000. Macroview Investment Management LLC grew its stake in Pfizer by 70.0% during the 1st quarter. Macroview Investment Management LLC now owns 962 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 396 shares in the last quarter. Finally, GeoWealth Management LLC purchased a new position in Pfizer during the 1st quarter valued at about $49,000. Institutional investors and hedge funds own 68.05% of the company’s stock.
Pfizer Stock Performance
PFE opened at $32.69 on Monday. Pfizer Inc. has a 12-month low of $32.50 and a 12-month high of $54.93. The firm has a market capitalization of $184.57 billion, a P/E ratio of 8.69, a price-to-earnings-growth ratio of 1.09 and a beta of 0.59. The stock’s 50 day moving average price is $35.53 and its two-hundred day moving average price is $37.70. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.
Pfizer (NYSE:PFE – Get Free Report) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.57 by $0.10. The firm had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $13.36 billion. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The business’s quarterly revenue was down 54.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.04 EPS. On average, equities analysts forecast that Pfizer Inc. will post 3.33 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Barclays decreased their target price on shares of Pfizer from $40.00 to $38.00 in a research note on Tuesday, July 11th. Jefferies Financial Group reduced their price objective on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. JPMorgan Chase & Co. dropped their target price on Pfizer from $45.00 to $41.00 and set a “neutral” rating on the stock in a research report on Monday, July 17th. Cantor Fitzgerald reiterated an “overweight” rating and set a $75.00 price target on shares of Pfizer in a report on Monday, September 18th. Finally, HSBC initiated coverage on Pfizer in a report on Friday, July 14th. They issued a “buy” rating and a $50.00 price objective on the stock. Twelve equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $46.35.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.